Another experimental vaccination strategy (Prostvac-VF) consisting of a recombinant vaccinia virus expressing the prostate-specific antigen (PSA) and other co-stimulatory molecules has also shown promise in clinical trials of PCa [4,5,8]. The gene discussed is KLK3; the disease is posterior cortical atrophy.